A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

第3相完了 NCT05931380

対象疾患	Obesity
相	第3相
スポンサー	Eli Lilly and Company
ステータス	完了
参加者数	238 名
介入（薬剤）	Orforglipron
開始日	2023年7月31日
完了日	2025年6月19日
結果公開日	2026年7月20日

概要

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Percent Change From Baseline in Body Weight at Week 72

Baseline, Week 72 · percent change

Placebo QD	-0.63 ± 0.732 percent change
6 mg Orforglipron QD	-5.90 ± 0.866 percent change
12 mg Orforglipron QD	-8.69 ± 1.136 percent change
36 mg Orforglipron QD	-7.93 ± 1.063 percent change

p-value	<.001
LS Mean Difference (Final values)	-5.28 (95% CI -7.52–-3.03)

Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

Baseline to Week 72 · Percentage of Participants

Placebo QD	15.00 Percentage of Participants
6 mg Orforglipron QD	45.90 Percentage of Participants
12 mg Orforglipron QD	61.40 Percentage of Participants
36 mg Orforglipron QD	58.33 Percentage of Participants

p-value	<.001
Risk Difference (RD)	30.36 (95% CI 15.09–45.62)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

Ignite Pilot: Goal Setting in a Digital Weight Loss Intervention — Stanford University
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects — University of Pennsylvania
Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
Time Restricted Eating for Weight Loss Maintenance — NYU Langone Health
Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Effect of PDE5 Inhibition on Adipose Metabolism in Humans — Vanderbilt University Medical Center

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский